Last updated on November 2019

Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations


Brief description of study

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.

Detailed Study Description

The study includes 3 cohorts with one primary endpoint (Objective Response Rate). Enrollment number and completion data is changed by new cohorts.

Clinical Study Identifier: NCT02864992

Find a site near you

Start Over